SCHEMBL29195800

SCHEMBL29195800

CCn1nc(Cc2c(F)cccc2Cl)n(CC2CCC(F)(F)CC2)c1=O

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ P2RX7 Q99572 3/20 0.40
▸ ADORA2A P29274 1/20 0.38
▸ ADORA2B P29275 1/20 0.38
▸ LMNA P02545 1/20 0.37
▸ KMT2A Q03164 2/20 0.36
▸ MEN1 O00255 1/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ ALOX15 P16050 1/20 0.34
▸ CASP1 P29466 1/20 0.34
▸ BRCA1 P38398 1/20 0.34
▸ CASP7 P55210 1/20 0.34
▸ HBB P68871 1/20 0.34
▸ CX3CR1 P49238 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29195788 0.94 LMNA (0.36) P2RX7ADORA2AADORA2BLMNAKMT2A
SCHEMBL29195769 0.92 P2RX7 (0.39) P2RX7ADORA2AADORA2BLMNAKMT2A
SCHEMBL29195848 0.90 P2RX7 (0.41) P2RX7ADORA2AADORA2BLMNAKMT2A
SCHEMBL29195810 0.89 P2RX7 (0.44) P2RX7ADORA2AADORA2BLMNATSHR
SCHEMBL30309029 0.89 P2RX7 (0.38) P2RX7ADORA2AADORA2BLMNAKMT2A
SCHEMBL29195783 0.89 TP53 (0.42) P2RX7ADORA2AADORA2BLMNAKMT2A
SCHEMBL29195801 0.88 ADORA2A (0.38) P2RX7ADORA2AADORA2BLMNAKMT2A
SCHEMBL29195799 0.87 P2RX7 (0.39) P2RX7ADORA2AADORA2BLMNAKMT2A
SCHEMBL30309032 0.87 P2RX7 (0.40) P2RX7ADORA2AADORA2BLMNASMN1; SMN2
SCHEMBL29195750 0.85 P2RX7 (0.48) P2RX7KMT2AMEN1TSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240368092-A1 2,4-Dihydro-3H-1,2,4-Triazol-3-One P2X7 Antagonists BREYE THERAPEUTICS APS (DK) 2024-11-07 — — US disclosed
EP-4396181-A1 2,4-DIHYDRO-3H-1,2,4-TRIAZOL-3-ONE P2X7 ANTAGONISTS Breye Therapeutics ApS (DK) 2024-07-10 — — EP disclosed
CN-117881675-A 2, 4-dihydro-3H-1, 2, 4-triazol-3-one P2X7 antagonists 布雷耶疗法有限公司 2024-04-12 — — CN disclosed
WO-2023031319-A1 2,4-DIHYDRO-3H-1,2,4-TRIAZOL-3-ONE P2X7 ANTAGONISTS AXXAM S.P.A. (IT) 2023-03-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368092-A1 2,4-Dihydro-3H-1,2,4-Triazol-3-One P2X7 Antagonists P2RX3, P2RX7, P2RX2 P2RX7 2/4885ADORA2A 20/4885ADORA2B 24/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback